3Sem.·

Gilead drug effectively protects against HIV infection $GILD (+0,07 %)


A six-monthly vaccination with the drug lenacapavir effectively protects against HIV infection.


This is confirmed by data from the pivotal Phase 3 study "Purpose 2", which is presented in the "New England Journal of Medicine" ("NEJM"). Astrid Berner-Rodoreda from Heidelberg University Hospital praised lenacapavir as a real breakthrough.


As a depot injection, lenacapavir provides long-term protection against HIV infection, with a booster scheduled every six months - previously used drugs for HIV pre-exposure prophylaxis (PrEP) such as Truvada must be taken daily as a tablet. Getting vaccinated twice a year is much more convenient than having to remember to take a tablet every day, said Berner-Rodoreda.


https://www.finanzen.net/nachricht/aktien/studie-gilead-aktie-steigt-gilead-wirkstoff-schuetzt-effektiv-vor-hiv-infektion-14054625

28.11
Gilead Sciences logo
Acheté x20 à 90,29 €
1 805,80 €
previw image
12
11 Commentaires

image de profil
super buy my friend
Voir toutes les 4 autres réponses
image de profil
Thanks for the info. I heard it on the radio today and didn't remember the name of the company. Keep your fingers crossed for your investment.😊🚀
Afficher la réponse
image de profil
Have you read up on who the stuff is actually intended for and who the most important target groups of "prep" are?
Voir toutes les 3 autres réponses
Participez à la conversation